Supplementary Figure S4 from Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors

Abstract

<p>Representative images of pHH3 immunostaining (200x magnification), comparing untreated vehicle-treated with imatinib, avapritinib 10 mg/kg or 30 mg/kg treated tumors in three models.</p>